Private Placement

A new 347 MW solar farm breaks ground near Houston, but the real story is the strategic international alliance and corporate demand fueling Texas's future.

Argo Corp. reports a stunning 680% revenue jump as its Smart Routing™ tech gains traction, securing new municipal contracts and a $10M investment.

Inflection Point’s latest SPAC closes a major IPO, but it’s not 2021. This is a story of seasoned players, mixed track records, and a hunt for real disruption.

Struggling battery firm Expion Energy makes a shocking pivot to oil and gas. The reason? The massive, unrelenting energy appetite of AI data centers in Louisiana.

A strategic merger combines Chemomab's promising drug, nebokitug, with Scipher's AI platform, aiming to de-risk development and transform RA treatment.

The electronics repair chain is rapidly expanding, but its repeated struggle to close a $2.5M financing round signals a deeper story about its financial health.

BioLineRx secures crucial funds for its cancer drugs, but at a cost. We dissect the deal, the shareholder dilution, and what it reveals about biotech financing.

A NASDAQ-listed shipping firm scuttles its entire fleet to become a digital asset powerhouse. SVRN's all-in bet on NEAR Protocol is a bold reinvention.

NexPoint's new marina fund reveals a trend: institutional cash flowing into niche waterfront assets. But are these safe harbors or risky waters for investors?

AIxCrypto is pivoting from crypto to a robot-sharing platform, touting a disciplined strategy. But with a 'going concern' warning, can it succeed?

Avenzo Therapeutics' new CHRO hire is more than a personnel move; it's a critical piece of a master plan for a public debut and oncology market disruption.

Machine Investment Group defies a tough market, raising $470M to hunt for distressed and special situation real estate in the often-overlooked middle market.

Leading Edge Materials nets C$4M in a strategic financing, fast-tracking its Swedish rare earth and graphite projects vital for the EU's green transition.

Errington Metals isn't just drilling; it's making a calculated move to redefine the Sudbury Basin. High-grade silver and a major financing signal a serious VMS play.

Diodes Inc. secures a massive, interest-free war chest. While markets flinched at the news, the move reveals a calculated strategy for acquisitions and growth.

Quince Therapeutics bets its future on an inhaled lung disease drug, LAM-001, after acquiring Orphai and securing a $115M financing to fuel its new mission.

Copenhagen Infrastructure Partners' new fund isn't just a number; it's a blueprint for how to de-risk and power the next wave of global growth.

With fully funded facilities and a US Army pact, REalloys is building a non-Chinese magnet supply chain. But can its strategic wins outweigh a $37M loss?

With a novel drug platform and new funding, Akari Therapeutics aims to redefine cancer therapy. But can its groundbreaking science outpace a ticking financial clock?

The InsurTech firm posted a Q2 loss and falling revenue, but its forward-looking metrics tell a different story. A deep dive into a high-stakes bet on AI.